Cargando…
CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
BACKGROUND: T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface antigen on several immune cells. It has been suggested that lymphocyte depletion increases the risk...
Autores principales: | Hotta, Ryuichi, Ohira, Masahiro, Matsuura, Toshiharu, Muraoka, Izumi, Tryphonopoulos, Panagiotis, Fan, Ji, Tekin, Akin, Selvaggi, Gennaro, Levi, David, Ruiz, Phillip, Ricordi, Camillo, Vianna, Rodrigo, Ohdan, Hideki, Waldmann, Herman, Tzakis, Andreas G., Nishida, Seigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999148/ https://www.ncbi.nlm.nih.gov/pubmed/27560943 http://dx.doi.org/10.1371/journal.pone.0161618 |
Ejemplares similares
-
Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022) -
Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
por: Li, Z., et al.
Publicado: (2018) -
CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation
por: Shafiei-Jahani, Pedram, et al.
Publicado: (2021) -
Propylthiouracil-Induced Acute Liver Failure: Role of Liver Transplantation
por: Carrion, Andres F., et al.
Publicado: (2010) -
Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)